Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Low muscle strength, BMI in young males predict eventual ALS

07 Feb 2018

In healthy, young males, low muscle strength, body mass index (BMI) and erythrocyte volume fraction predict amyotrophic lateral sclerosis (ALS) later in life, a recent study has shown.

The researchers performed a prospective cohort study on 1,819,817 young males with an average age of 18.3±0.7 years. Over the 46-year follow-up period, 526 participants were diagnosed with ALS. The median age at first diagnosis was 50.0 years.

Baseline BMI was significantly lower in those who eventually developed ALS than in those who did not (21.9±3.0 vs 21.1±2.5 kg/m2; p=0.03). Difference in baseline muscle strength also showed a trend toward significance, wherein low muscle strength was more common in those who developed ALS later in life (p=0.06 for trend).

Mean erythrocyte volume fraction was likewise significantly lower in those who developed ALS than in those who did not (46.4±2.4 percent vs 46.2±2.5 percent; p=0.05).

The same trends were observed in a multivariate logistic regression model adjusted for potential confounders. For instance, BMI (hazard ratio [HR], 0.96; 95 percent CI, 0.93–0.99) remained a significant predictor of eventual ALS. Erythrocyte volume fraction was also significantly correlated with the risk of ALS (HR, 0.96; 0.92–0.998).

Finally, relative to high muscle strength at baseline, low muscle strength was likewise significantly predictive of ALS development later in life (HR, 1.36; 1.01–1.83).

In contrast, there appears to be no correlation between the risk of eventual ALS and erythrocyte sedimentation rate, physical fitness at baseline, parental education or psychiatric disorders.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.